AUTHOREA
Log in Sign Up Browse Preprints

loading page

Linear IgA Bullous Dermatosis and Elevated Bullous Interleukin-6 Levels: Responsive to Treatment with Anti-IL-6 Receptor Monoclonals
  • +5
  • Stanley Jordan,
  • Bonnie Balzer,
  • Cynthia Nast,
  • Janet Atienza,
  • Katherine Lim,
  • Sanjeev Kumar,
  • Nicholas N. Nissen,
  • Bongha Shin
Stanley Jordan
Cedars-Sinai Medical Center

Corresponding Author:[email protected]

Author Profile
Bonnie Balzer
Cedars-Sinai Medical Center
Author Profile
Cynthia Nast
Cedars-Sinai Medical Center
Author Profile
Janet Atienza
Cedars-Sinai Medical Center
Author Profile
Katherine Lim
Cedars-Sinai Medical Center
Author Profile
Sanjeev Kumar
Cedars-Sinai Medical Center
Author Profile
Nicholas N. Nissen
Cedars-Sinai Medical Center
Author Profile
Bongha Shin
Cedars-Sinai Medical Center
Author Profile

Abstract

Linear IgA bullous dermatosis (LABD) is an autoimmune/inflammatory skin condition. Here, we report on a patient who developed treatment resistant LABD. At diagnosis, elevations of IL-6 and C-reactive protein in the blood and extreme elevations in LABD bullous fluid were seen. The patient responded well to tocilizumab (anti-IL-6 receptor) treatment.

Peer review status:ACCEPTED

05 Dec 2022Submitted to Clinical Case Reports
Show details
Hide details
08 Dec 2022Submission Checks Completed
08 Dec 2022Assigned to Editor
15 Dec 2022Reviewer(s) Assigned
19 Dec 2022Review(s) Completed, Editorial Evaluation Pending
19 Dec 2022Editorial Decision: Revise Minor
09 Feb 20231st Revision Received
10 Feb 2023Submission Checks Completed
10 Feb 2023Assigned to Editor
10 Feb 2023Review(s) Completed, Editorial Evaluation Pending
12 Feb 2023Editorial Decision: Accept